- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01719861
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
Participants will start desipramine by mouth nightly (QHS) for 6 weeks, with weekly dose escalation. Starting dose will be 25 to 75 mg. The desipramine dose will be escalated until the maximum dose of 450 mg is reached or a maximum safe dose per subject is established.
Dose level may be adjusted (decreased) based on cardiac or general adverse effects. desipramine level will be tapered if the subject experience disease progression, unless physician judges immediate suspension is in the subjects best interest.
Assessments will be conducted every 28 days, and will include ECGs, physicians and blood samples.
One partial and/or complete response will be sufficient to consider a larger clinical trial.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Metastatic small-cell lung cancer
- Metastatic high-grade neuroendocrine carcinoma of any organ system (high-grade defined by Ki-67 ≥ 20% and/or ≥ 20 mitoses/10 (HPF).
- Received at least one line of prior chemotherapy treatment for metastatic disease.
- Daily chemotherapy must be completed ≥ 2 weeks prior to registration
- Weekly chemotherapy must be completed ≥ 2 weeks prior to registration
- Chemotherapy every 2 weeks must be completed ≥ 3 weeks prior to registration
- Chemotherapy every 3 weeks must be completed ≥ 4 weeks prior to registration
- ECOG Performance Status 0 to 2
- Measurable disease by RECIST 1.1 criteria
- Age at least 18 years
- Estimated life expectancy at least 3 months
- Absolute neutrophil count ≥ 1,500/ mm³
- Platelets ≥ 100,000/mm³
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 mg/dL, OR ≤ 2 X ULN if tumor involves the liver
- AST(SGOT)
- ALT(SGPT) ≤ 3 X ULN
- Creatinine ≤ 1.5 X ULN
- Creatinine clearance ≥ 45 mL/min/1.73m²) for patients with creatinine levels above institutional normal
- QT interval corrected using Fridericia's method (QTcF) < 450 msec (males) or < 470 msec (females)
- PR < 240 msec
- QRS < 100 msec
- Brain metastases must be asymptomatic and have been adequately treated with radiation finishing at least 1 week prior to initiation of study treatment.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Clinically-significant ventricular arrhythmia including cardiac arrest
- Myocardial infarction from coronary artery disease within 3 months of study enrollment
- Implantable pacemaker or implantable cardioverter defibrillator
- NYHA Class III or greater congestive heart failure
- Other clinically-significant cardiac disorders
- Family history of long QT syndrome.
- Concomitant or expected treatment with strong inhibitors of cytochrome p450 CYP2D6, specifically including Bupropion; Fluoxetine; or Paroxetine (must be discontinued at least 2 weeks or 5-half lives prior to the initiation of desipramine, whichever is shortest, except fluoxetine which requires at least a 5-week washout period).
- Use of medications known to increase risk of torsades de pointes, including Amiodarone; Arsenic trioxide; Astemizole; Azithromycin; Bepridil; Chloroquine; Chlorpromazine; Cisapride; Citalopram; Clarithromycin; Disopyramide; Dofetilide; Domperidone; Droperidol; Erythromycin; Flecainide; Halofantrine; Haloperidol; Ibutilide; Levomethadyl; Mesoridazine; Methadone; Moxifloxacin; Pentamidine; Pimozide; Probucol; Procainamide; Quinidine; Sotalol; Sparfloxacin; Terfenadine; Thioridazine; Vandetanib
- Other anti-depressant or anti-psychotic medications including selective serotonin re-uptake inhibitors (SSRIs); other tricyclic, monoamine oxidase inhibitors (MAOIs); serotonin-norepinephrine reuptake inhibitors (SNRIs, typical or atypical anti-psychotic)
- Metoclopramide (Reglan) because of increased risk of extrapyrimidal symptoms and neuroleptic malignant syndrome
- Symptomatic orthostatic hypotension despite adequate volume resuscitation.
- Medical history of narrow angle glaucoma
- Bipolar disorder, ongoing or active within the last 5 years
- Suicidal ideation, ongoing or active within the last 5 years
- Suicide attempt, ongoing or active within the last 5 years
- Pregnancy
- Breastfeeding
- Receiving any other investigational agents
- Any other serious or unstable concomitant systemic disorder that in the opinion of the investigator is incompatible with the clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Desipramine HCl
Desipramine is a tricyclic antidepressant (TCA).
|
Desipramine is a tricyclic antidepressant (TCA).
All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks.
The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: 6 weeks
|
Overall response rate (ORR) was assessed as the number of patients who achieve either a partial (PR) or complete response (CR) measured by CT scans and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria, divided by the total number of patients treated on the study.
CR: Disappearance of all target lesions, all non-target lesions, and no new lesion.
PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Desipramine Maximum Dose
Time Frame: Up to 6 weeks
|
Assessed as the median per patient maximum dose (MD) using intra-patient dose escalation, and reported as the highest dose of desipramine administered continuously for 1 week or greater.
|
Up to 6 weeks
|
Median Serum Desipramine Levels During Treatment
Time Frame: Up to 6 weeks
|
Median serum desipramine levels during treatment is reported as the median of the maximum steady state serum concentration observed in all patients. Therapeutic concentration of desipramine is 100 to 300 ng/mL, and toxic concentration is > 300 ng/mL. |
Up to 6 weeks
|
Progression-free Survival (PFS), Median
Time Frame: Up to 5 years from enrollment to radiographic progression or drug discontinuation
|
Median PFS was defined as the time from randomization to disease progression (or death if the patient died before progression) calculated using the Kaplan-Meier method.
|
Up to 5 years from enrollment to radiographic progression or drug discontinuation
|
Median Overall Survival (OS)
Time Frame: From start of enrollment until death, no limit
|
Median overall survival was defined as time from enrollment to death from any cause calculated using the Kaplan-Meier method.
|
From start of enrollment until death, no limit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joel W Neal, MD, PhD, Stanford University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Neuroendocrine Tumors
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Adrenergic Uptake Inhibitors
- Desipramine
Other Study ID Numbers
- IRB-25491
- VAR0087 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Francesco De CobelliCompleted
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
Oslo University HospitalUniversity Hospital of North Norway; Haukeland University Hospital; St. Olavs...RecruitingPancreatic Neuroendocrine Tumors, WHO Grade I-IINorway
Clinical Trials on Desipramine HCL
-
SandozCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Boehringer IngelheimCompleted
-
University of Kansas Medical CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Daiichi Sankyo, Inc.TerminatedType 2 Diabetes MellitusUnited States
-
BioCryst PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL)United States, Australia
-
Daiichi Sankyo Co., Ltd.Completed